BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:BCT - CA1079303071 - Common Stock
BCT.CA Key Statistics, Chart & Performance
The current stock price of BCT.CA is 11.24 CAD. In the past month the price decreased by -22.48%. In the past year, price decreased by -99.04%.
BCT.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 507.51M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 367.23M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.71 | 47.78M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 31.97M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 25.86M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.02M | ||
| MPH.CA | MEDICURE INC | N/A | 12.63M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.54M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About BCT.CA
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William Williams
Employees: 20
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCT.CA FAQ
What does BCT do?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
What is the current price of BCT stock?
The current stock price of BCT.CA is 11.24 CAD. The price increased by 5.44% in the last trading session.
Does BCT stock pay dividends?
BCT.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCT stock?
BCT.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is BCT.CA stock listed?
BCT.CA stock is listed on the Toronto Stock Exchange exchange.
What is BRIACELL THERAPEUTICS CORP worth?
BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 21.13M CAD. This makes BCT.CA a Nano Cap stock.
BCT.CA Technical Analysis
BCT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCT.CA. While BCT.CA has a great health rating, there are worries on its profitability.
BCT.CA Financial Highlights
Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -175.4. The EPS decreased by -184.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.59% | ||
| ROE | -146.16% | ||
| Debt/Equity | 0 |